Anxiety and Fear
Conditions
Brief summary
Background: Different intravenous sedative drugs have been utilized for colonoscopy, with many anesthetists for painless sedation or monitored anesthesia care. The aim of this study was the quality of colonoscopy and the incidence of adverse events such as respiratory depression, hemodynamic instability, and failure to provide adequate sedation.
Detailed description
Background: Different intravenous sedative drugs have been utilized for colonoscopy, with many anesthetists for conscious sedation or monitored anesthesia care. Aim of this study was the quality of colonoscopy and the incidence of adverse events such as respiratory depression, hemodynamic instability, and failure to provide adequate sedation. Patients and methods: Sixty patients of both sexes and 21-60 years old with ASA physical status I-II, were randomly assigned to receive either dexmedetomidine (D group) or propofol-fentanyl (PF group) infusions in equal numbers. Minimal infusion rates of dexmedetomidine (0.1-0.4 μg/kg/h) in the D group and fentanyl (0.01-0.05 μg/kg/min) in the PF group were continued during colonoscopy, which lasted approximately 30 minutes.
Interventions
DRUGPatients who received Dexmedetomodine
1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
DRUGpatients who received propofol-fentanyl
Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
Sponsors
Al-Azhar University
Zulekha Hospitals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Inclusion Criteria: 1. both sexes 2. 21-60 years old, with 3. ASA physical status - *
Exclusion criteria
* severe cardiovascular or respiratory disease * (ASA grade ≥III) * pregnancy * allergies to the drugs being used * known alcohol or substance abuse * expected communication difficulties with the patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The quality of painless sedation during colonoscopy. | From start of procedure to 120 minutes after end of colonoscopy | The patient's ability to cooperate and perform the procedure was evaluated using a 10-point numerical rating scale (NRS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence of adverse events, Prevalence of adverse effects | from start of procedure to 120 minutes after end of colonoscopy | incidence of adverse events, hemodynamic instability, failure to provide adequate sedation. |
Countries
Egypt
Outcome results
None listed